If I’d invested £1,000 in the Haleon shares spin-off, here’s how much I’d have now

Haleon shares have been public for almost a year but investors remain hawkish over looming legal risks. Zaven Boyrazian investigates further.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Young Black woman looking concerned while in front of her laptop

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s almost been a year since Haleon (LSE:HLN) shares were spun out from GSK. And while we’re still in the early days, the consumer healthcare company seems to be making solid progress. So let’s take a closer look at what’s been going on since the stock went public.

Off to a good start

Last month, Haleon announced its first-quarter trading results. Despite what the slight dip in valuation would suggest, both sales and profits were up by double-digits.

Total revenue grew by a solid 13.7%, with its Respiratory Health division leading the charge delivering 33% organic growth. Its Vitamins, Minerals and Supplements (VMS) segment sadly shrank by 3.7% year-on-year. However, a closer inspection of the underlying cause reveals some tough comparisons.

In 2022, VMS enjoyed some notable tailwinds from Covid-19 as demand for its Emergen-C tablets shot up in North America. With the pandemic no longer disrupting the world, Emergen-C sales have since normalised.

Over on the profit side of the equation, operating income is up by a chunky 34.5% reaching £627m. However, it’s important to note this boost largely stems from eliminating administrative expenses related to the demerger from GSK. Ignoring these effects, underlying earnings were up by just 9.5%.

That’s far from terrible. But with the currency exchange rate fluctuating, the group couldn’t maintain margins resulting in adjusted operating profitability dropping by 0.9% to 23.1%.

Nevertheless, management remains confident of hitting the higher end of its previously issued 4-6% organic revenue growth guidance, as well as staying on track with its projected earnings. So how have Haleon shares reacted to all this?

Haleon share price performance

While the financials appear to be moving in the right direction, there’s still a lot of work to be done. And it seems other investors share this opinion when looking at how the stock has performed since going public last year.

Haleon shares are up a not-so-grand total of just 2%. That’s nearly half of what the FTSE 100 has delivered before considering dividends.

At an opening price of 330p in July 2022, investing £1,000 into the stock would have fetched approximately 303 shares. Combining the 2.4p dividend per share paid earlier this year with the 2% price gain, the investment would currently be worth around £1,027.27.

Those are hardly the most exciting returns out there. But after a year of independence, the management team has had some time to demonstrate its skill. And while it has yet to be reflected through investment gains, the business seems to be on track.

Having said that, I’m still on the sidelines. Several question marks remain unanswered, the biggest of which is the ongoing litigation surrounding Zantac. Allegations have been made that the drug causes cancer, and while out-of-court settlements are being made, there remains the risk of severe legal penalties. And if Haleon becomes exposed to these penalties, it could easily undo the progress made so far..

Therefore, I’m not tempted to add any Haleon shares to my portfolio today. But I will be keeping a close eye on how the situation develops.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has recommended Haleon Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Black man sat in front of laptop while wearing headphones
Investing Articles

Down 53% in a year! I reckon this oversold FTSE 100 stock is now ripe for a comeback

This FTSE 100 stock has fallen out of fashion with investors, but Harvey Jones reckons the sell-off has gone too…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

How much second income would I get if I put £10k into dirt cheap Centrica shares?

Centric shares have been looking incredibly cheap despite rocketing in recent years. Harvey Jones wonders whether this is an opportunity…

Read more »

artificial intelligence investing algorithms
Investing Articles

If I’d invested £10k in AstraZeneca shares three months ago here’s what I’d have now

Harvey Jones is kicking himself for failing to buy AstraZeneca shares before the took off. Is there still a decent…

Read more »

A senior group of friends enjoying rowing on the River Derwent
Investing Articles

How I’d find shares to buy for an early retirement

Christopher Ruane explains some of the factors he considers when looking for shares to buy that could potentially help him…

Read more »

Investing Articles

Why I’d snap up bargain UK shares to try and build wealth

Christopher Ruane explains how he hopes to find high-quality UK shares selling at attractive prices, to help him build wealth…

Read more »

Young Caucasian woman at the street withdrawing money at the ATM
Investing Articles

Here’s how I’d target a £2k annual second income from a £20k Stocks & Shares ISA

Our writer explains how he’d try to earn thousands of pounds annually in dividends by investing a £20k ISA in…

Read more »

Mother and Daughter Blowing Bubbles
Investing Articles

5 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Investing Articles

The £20k Stocks and Shares ISA might be one of the better things about living in the UK

The £20k Stocks and Shares ISA doesn't have many equivalents in other countries. Here's why these accounts can help UK…

Read more »